single10MG
Trizepatide
10MG Protocol
Trizepatide 10MG
Injection Freq.
Inject once weekly
Cycle Sched.
Weekly subcutaneous injection on the same day each week for 12–16+ weeks
Reconstitution
2.0 mL BAC water
Significant HbA1c reductions reported in type 2 diabetes trials
Substantial body-weight loss reported in clinical trials
Improvements in lipid profile and blood pressure reported in some studies
Once-weekly dosing convenience
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2.5 mg | 50 |
| 2 | Weeks 5–8 | 5 mg | 100 |
| 3 | Weeks 9–12 | 7.5 mg | 75 |
| 4 | Weeks 13–16 | 10 mg | 100 |
Inject once weekly
Weekly subcutaneous injection on the same day each week for 12–16+ weeks
The Trizepatide (tirzepatide) 10 mg protocol describes an incretin-based dual agonist mechanism. By simultaneously activating GLP-1 and GIP receptors, Trizepatide is described as improving glycemic control through glucose-dependent insulin secretion and reduced glucagon output. In parallel, it delays gastric emptying and increases satiety via central appetite pathways, reducing food intake and supporting weight loss. The protocol emphasizes that GIP receptor activation may amplify metabolic outcomes beyond GLP-1 activity alone, which aligns with clinical-trial results reporting large body-weight reductions at higher doses. A half-life around 5 days allows once-weekly administration, which supports consistent exposure while simplifying scheduling. Overall, the ‘how it works’ narrative is dual incretin signaling that targets both appetite/gastric emptying and glucose regulation, with dose-dependent gastrointestinal effects mitigated by gradual titration.
Nausea
Diarrhea
Vomiting
Constipation
Mild injection-site reactions (redness/irritation)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)